Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04404595 · ClinicalTrials.gov registry record · Phase 1

Claudin18.2 CAR-T (CT041) in Patients with Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

A Phase 1 study of Pancreatic Cancer and Gastric Cancer, sponsored by CARsgen Therapeutics Co..

Active
Registry status
Phase 1
Development phase
110
Enrollment target
16
Study locations

NCT04404595 is a Phase 1 study of Pancreatic Cancer and Gastric Cancer that is active but no longer recruiting, run by CARsgen Therapeutics Co.. The registered enrollment target is 110 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (72% lower). The trial reports 16 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04404595, a Phase 1 study of Pancreatic Cancer and Gastric Cancer, is active but no longer recruiting, sponsored by CARsgen Therapeutics Co..

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
110 participants
Enrollment target
16
Study locations

Study Summary

A Phase 1b/2, open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic or other specified digestive system cancers

Conditions Studied

Pancreatic Cancer Gastric Cancer

Interventions

  • BIOLOGICAL CT041

Study Locations (16)

California

  • City of Hope - Duarte
  • University of Southern California - Los Angeles
  • UCSD - San Diego
  • UCSF - San Francisco

New York

  • Northwell Cancer Institute - New Hyde Park
  • The Mount Sinai Hospital - New York
  • Memorial Sloan Kettering Cancer Center - New York

Texas

  • TX Oncology-Baylor Charles Sammons Cancer Center - Dallas
  • MD Anderson Cancer Center - Houston

Florida

  • Moffitt Cancer Center - Tampa

Kansas

  • University of Kansas Cancer Center - Kansas City

Michigan

  • Karmanos Cancer Center - Detroit

Minnesota

  • Mayo Cancer Hospital - Rochester

Ohio

  • Ohio State University - Columbus

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2020-10-23
Est. Completion 2035-09-01
Phase Phase 1

Sponsor

CARsgen Therapeutics Co.

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04404595

The ClinicalTrials.gov registry entry for NCT04404595 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (72% lower). The listed sponsor is CARsgen Therapeutics Co., which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which CT041 is the first listed.

NCT04404595 reports 16 study locations spanning 10 distinct geographic areas - top geographies include California, New York, Texas.

Frequently Asked Questions

What is clinical trial NCT04404595 about?

NCT04404595 is a clinical study titled "Claudin18.2 CAR-T (CT041) in Patients with Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers". A Phase 1b/2, open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic or other specified digestive system cancers

What is the current status of trial NCT04404595?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2020-10-23. Estimated completion is 2035-09-01.

What conditions does trial NCT04404595 study?

This clinical trial studies the following conditions: Pancreatic Cancer, Gastric Cancer.

What interventions are being tested in trial NCT04404595?

The interventions under investigation include: CT041 (BIOLOGICAL).

Who is sponsoring clinical trial NCT04404595?

This trial is sponsored by CARsgen Therapeutics Co., which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04404595 being conducted?

This trial has 16 study locations across California, Florida, Kansas, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreatic Cancer

All registered trials for this condition

Gastric Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.